Becton, Dickinson and Company BDX is benefiting from its focused transformation into a pure-play MedTech company, supported by strong execution of its BD 2025 strategy. The company’s continued ...

Becton, Dickinson (NYSE:BDX) is gearing up to announce its quarterly earnings on Monday, 2026-02-09. Here's a quick overview of what investors should know before the release. Analysts are estimating ...

Thomas Polen, President, CEO & Chairman, reported that "Q4 revenue of $5.9 billion increased 7% and 3.9% organic. New BD delivered strong organic growth of 4.9%, accelerating 90 basis points ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. Featuring daily updates ...

We initiated a long position in Becton, Dickinson and Company common stock during the quarter. Most of its revenue comes from selling low-priced yet essential consumable medical supplies and devices ...

In the latest quarter, 7 analysts provided ratings for Becton Dickinson (NYSE:BDX), showcasing a mix of bullish and bearish perspectives. The table below provides a snapshot of their recent ratings, ...

Becton, Dickinson and Company will shell out $110 million to expand prefillable syringe production at its Columbus, Nebraska, manufacturing plant. The move comes in response to increasing delivery ...

Becton, Dickinson & Co (Symbol: BDX) has been named a Top Socially Responsible Dividend Stock by Dividend Channel, signifying a stock with above-average ''DividendRank'' statistics including a strong ...

Aristotle Atlantic Partners, LLC, an investment advisor, released its “Core Equity Strategy” third-quarter 2025 investor letter. The letter highlighted the market review, quarterly performance, and ...